ASH News Daily 2014 - Day 2 - (Page A-1)

Read this issue online at Follow us on Twitter using #ASH14 Schedule 7:00 - 9:00 a.m. Hematology Course Directors' Workshop Westin Market Street, Franciscan Ballroom 9:30 - 11:00 a.m. Special Scientific Symposium on Chimeric Antigen Receptor T Cell Therapy West Building, Rooms 3007-30093011-3020-3022-3024 11:15 a.m. - 12:15 p.m. Continuing Conversations with the Speakers Moscone Center (South Building, Esplanade 301-302) 11:15 a.m. - 12:15 p.m. Featured Topic Discussion: Hot Topics and Targets in Hemostasis and Thrombosis North Building, Rooms120-125 11:15 a.m. - 12:30 p.m. ASH Practice Partnership Lunch Westin Market Street, Metropolitan Ballroom 12:30 - 1:30 p.m. ASH/EHA Joint Symposium North Building, Hall D 1:30 - 2:00 p.m. Announcement of Wallace H. Coulter Award North Building, Hall D 2:00 - 4:30 p.m. Plenary Scientific Session North Building, Hall D 6:30 - 7:30 p.m. The HVO Volunteer Experience: Sharing Your Hematology Expertise Globally South Building, Esplanade 301 IN THIS SECTION Myeloma A-2 MDS A-6 Sickle Cell Disease A-10 MPNs A-14 Dr. Hagop Kantarjian (from left), Dr. Andreas Laupacis, Alex Bastian, MBA, and Dr. S. Yousuf Zafar participate in a panel discussion chaired by Drs. Lisa Hicks and Mark Crowther during the Special Symposium on Quality of Care. Don't Shoot the Messenger cent of which goes toward treating cancer. As more people are diagnosed with cancer, the number of chemotherapy agents hitting the market has increased exponentially, and so has the cost. In 2012, the U.S. By ifeyinwa (ify) OSunkwO, Md, MPh N early 20 percent of the U.S. gross domestic product is spent on health care, 5 perFood and Drug Administration approved three new drugs for chronic myeloid leukemia (CML) that cost $100,000 per year - nearly five times more than imatinib (Gleevec) cost in 2001. Part of this cost is increasingly being shifted to the patient, leading to significant financial toxicity that does not always translate to improved survival. On Saturday, the Special Symposium on Quality continued the frank and impassioned discussion about the ethics and morals of the rising price tag of cancer care. How can we best reduce the burden of this cost without compromising clinical outcomes? Why do new cancer drugs cost so much more in the United States than elsewhere? Does this price tag reflect clinical benefit? More importantly, should a physician introduce the concept of "cost-effectiveness" to the patient? »» QUALITY Page A-19 Understanding a Sticky Situation By MaiSSaa JanBain, Md T hromboembolism remains a sticky topic with a lot of unanswered questions facing the daily practice of medicine for both generalists and specialists. The lack of compelling evidence available to guide thromboembolic event management (especially in certain subpopulations) as well as the knowledge gaps regarding the newer anticoagulants, obscure our therapeutic choices and decisions. This year, there are two dedicated education sessions on the management of thromboembolic events. In the first session, titled "New Paradigms in Anticoagulation and Thrombolysis," presented yesterday, Dr. Stephan Moll from the University of North Carolina, Chapel Hill, Dr. William Geerts from Sunnybrook Health Center in Toronto, and Dr. Agnes Lee from the University of British Columbia in Vancouver reviewed the management of thromboembolism including recent advancements, while focusing in particular on challenging scenarios of thrombosis in patients with cancer and in catheter-related thrombosis (CRT). Dr. Moll discussed »» THROMBOSIS Page A-6

Table of Contents for the Digital Edition of ASH News Daily 2014 - Day 2

Table of Contents

ASH News Daily 2014 - Day 2